Compass Therapeutics

CMPX · NASDAQ

$0.8333−$0.0017 (−0.20%)TodayMarket closed · Oct 20, 7:39 PM ET

Prev close $0.835

Latest news

NewsSep 22, 2:26 PM ETAvi Kapoor
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
NewsSep 22, 2:02 PM ETVandana Singh
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
NewsSep 22, 9:43 AM ETAvi Kapoor
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
Press releaseSep 22, 8:30 AM ETGlobe Newswire
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Press releaseAug 6, 7:30 AM ETGlobe Newswire
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Press releaseJul 17, 10:42 AM ETGlobe Newswire
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Press releaseJun 30, 9:00 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Press releaseJun 12, 8:10 AM ETGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Press releaseMay 21, 5:00 PM ETGlobe Newswire
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Press releaseMay 19, 6:09 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Press releaseMay 14, 11:01 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Press releaseMay 12, 4:45 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Press releaseMay 5, 7:30 AM ETGlobe Newswire
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Press releaseApr 30, 7:42 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NewsApr 30, 12:48 PM ET
Compass Therapeutics Option Alert: Jul 17 $2 Calls Sweep (11) Near The Ask: 1191 @ $0.351 Vs 33 OI; Earnings 5/11 Before Open [Est] Ref=$1.765
NewsApr 27, 12:21 PM ETAvi Kapoor
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings
NewsApr 27, 11:44 AM ETVandana Singh
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
NewsApr 27, 10:03 AM ETAvi Kapoor
US Stocks Mixed; Nasdaq Falls Over 100 Points
NewsApr 27, 8:02 AM ETAvi Kapoor
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseApr 27, 7:30 AM ETGlobe Newswire
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
NewsApr 27, 7:18 AM ET
Market-Moving News for April 27th
Press releaseMar 5, 7:30 AM ETGlobe Newswire
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Press releaseMar 2, 5:31 PM ETPRNewswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
Press releaseJan 14, 10:39 AM ETGlobe Newswire
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
NewsJan 7, 10:03 AM ETAvi Kapoor
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
Press releaseJan 6, 8:00 AM ETGlobe Newswire
Compass Therapeutics Provides Corporate Update
NewsJan 5, 1:06 PM ETVandana Singh
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care
Press releaseNov 5, 7:30 AM ETGlobe Newswire
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Press releaseAug 11, 7:00 AM ETGlobe Newswire
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
NewsAug 11, 4:32 AM ET
Earnings Scheduled For August 11, 2025
Press releaseMay 8, 8:00 AM ETGlobe Newswire
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
Press releaseApr 28, 8:00 AM ETGlobe Newswire
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
NewsMar 31, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseJan 8, 8:00 AM ETGlobe Newswire
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Press releaseNov 12, 8:00 AM ETGlobe Newswire
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Press releaseOct 4, 10:31 AM ETGlobe Newswire
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Press releaseAug 12, 8:00 AM ETGlobe Newswire
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

Compass Therapeutics Option Alert: Jul 17 $2 Calls Sweep (11) Near The Ask: 1191 @ $0.351 Vs 33 OI; Earnings 5/11 Before Open [Est] Ref=$1.765

Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

US Stocks Mixed; Nasdaq Falls Over 100 Points

Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Market-Moving News for April 27th

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

Compass Therapeutics Provides Corporate Update

Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Earnings Scheduled For August 11, 2025

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

12 Health Care Stocks Moving In Monday's After-Market Session

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update